A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN) - Trial NCT06104644
Access comprehensive clinical trial information for NCT06104644 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 450 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bristol-Myers Squibb
Timeline & Enrollment
N/A
Apr 13, 2023
Apr 30, 2030
Primary Outcome
Proportion of patients achieving an absolute Psoriasis Area Severity Index (aPASI) score ≤ 3 at Week 24 or nearest visit
Summary
The purpose of this observational study is to describe the effectiveness of deucravacitinib
 treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine
 clinical practice in Germany over a 5-year period
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06104644
Non-Device Trial